Tumor markers AFP, CA 125, and CA 19-9 in the long-term follow-up of sacrococcygeal teratomas in infancy and childhood.

Abstract

Given the tendency of a proportion of sacrococcygeal teratomas (SCT) to recur, we evaluated whether serial tumor marker measurements are helpful in the management of these children. Between 1985 and 2006, 32 children with SCT were followed up for 1-15 years, and a total of 344, 197, and 193 serial samples for serum alpha-fetoprotein (AFP), CA 125, and CA 19-9 were analyzed, respectively. Six children with neonatal SCT developed eight recurrences. Serum AFP was elevated in two of two children prior to diagnosis of malignant recurrences (yolk sac tumor and adenocarcinoma), and CA 125 was elevated in one third of mature and one third of immature recurrences. CA 19-9 remained within reference values in relation to recurrences of neonatal SCT. Taken together, serum CA 125 measurements may complement the use of serum AFP in the follow-up of SCT.

• Authors: Satu-Liisa Pauniaho, Olga Tatti, Pekka Lahdenne, Harry Lindahl, Mikko Pakarinen, Risto Rintala, Markku Heikinheimo
• Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (Tumour Biol) Vol. 31 Issue 4 Pg. 261-5 (Aug 2010) ISSN: 1423-0380 [Electronic] Netherlands
• PMID: 20361286 (Publication Type: Journal Article)

Chemical References

• CA-125 Antigen
• CA-19-9 Antigen
• alpha-Fetoproteins

Topics

• CA-125 Antigen (blood)
• CA-19-9 Antigen (blood)
• Female
• Follow-Up Studies
• Humans
• Immunoenzyme Techniques
• Infant, Newborn
• Male
• Prognosis
• Sacrococcygeal Region (pathology)
• Spinal Neoplasms (blood, pathology)
• Survival Rate
• Teratoma (blood, pathology)
• Time Factors
• alpha-Fetoproteins (metabolism)